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Abstract
Introduction: Imatinib mesylate has become the choice of drug in the treatment of chronic
myeloid leukemia. Objective: To study safety profile of Imatinib (specific inhibitor or bcr-
abl tryosne kinase protein) in Philadelphia chromosome t {(9:22), bcr-abl}   positive chronic
myeloid leukemia (CML) chronic phase patients. Materials and Methods: After IEC
clearance, 36, BCR-ABL positive CML patients in the chronic phase of the disease were
recruited. Imatinib mesylate (Gleevec, Novartis), was started (400mg daily) and followed
up weekly in first month, two weekly till three months & monthly thereafter. Safety profile
data, recorded in pre-designed proforma, were analyzed for time of onset, duration and
severity of adverse effects. Causality relationship of recorded adverse events was established
with imatinib therapy using WHO-UMC criteria. Results: A total of 222 adverse events
were reported in 36 CML-CP patients over 12 months of follow up. Thrombocytopenia was
the most commonly reported in 60% of the patients followed by musculoskeletal (17%),
dermatological (16%), gastrointestinal disturbances (13%), body weight changes (11%),
superficial edema (8%) and liver enzyme rise (4%). More than 80% events reported within
months of therapy which persisted for less than 3 months in most of the cases. No treatment
was needed in 68% of cases while therapy alteration was not needed in 88% of cases.
Most of the reactions (60%) had probable relationship with the therapy. Conclusion: Imatinib
was well tolerated, having only mild to moderate grade of toxicities, mostly within 3 months
of therapy and most of them persisted for less than 3 months of duration, requiring only
symptomatic treatment and drug withhold or dose decrement in only few cases.
Keywords: Safety profile, imatinib, causality assessment, adverse events.
Introduction
Imatinib mesylate, 2-phenyl amino pyridine, has
brought paradigm shift in the treatment of chronic
myeloid leukemia (CML) which is clonal stem cell
disorder in which cells of the myeloid series undergo
massive clonal expansion.1 CML is caused by
tyrosine kinase activity of fusion protein BCR-ABL
formed by the reciprocal translocation between the
long arm of chromosome 9 and 22.2I  Imatinib acts
by competitively blocking the ATP binding site at
BCR-ABL tyrosine kinase, so inhibiting the
phosphorylation of tyrosine residue of target protein
in the signal transduction pathway, hence excessive
cell proliferation occurring in CML is interrupted   and
apoptosis is induced.3 Imatinib is metabolized by liver
microsomal enzyme system mainly CYP3A4 and
CYP3A5.4 P-Glycoprotein expression in the
leukemia cells affect the bioavailability of the drug.5
Imatinib is well tolerated drug showing adverse
events of mild to moderate severity. The most
frequently reported adverse events during imatinib
therapy are nausea, vomiting, edema, muscle and
bone pains, arthralgia, skin rash, diarrhea, fatigue,
weight gain, hematological toxicity and hepatotoxicity
6,7
.  Severity and frequency of reported adverse
events increase with dose3 and in advanced phases
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of CML 6,8,9.   There are inter-individual and racial
variations in all of the above mentioned factors
affecting safety profile of the drug. Studies10, 11 in
Indian chronic myeloid leukemia patients has shown
different safety profile of imatinib from landmark
Western studies6,7. But data from these preliminary
Indian studies are not sufficient for making
conclusion. So we planned to record adverse events
of imatinib in newly diagnosed Indian chronic myeloid
leukemia patients, establish causal relationship of
these events with imatinib and compare these results
with landmark Western studies and previous Indian
studies.
Methodology
Chronic myeloid leukemia (CML) patients coming
to the Medical Oncology OPD, Dr. BRAIRCH,
AIIMS, New Delhi, between July, 2006 and June,
2007 were enrolled in the study according to following
criteria.
Inclusion criteria:- i.) All  age groups and both
sexes. ii.) Newly  diagnosed Philadelphia
chromosome or BCR-ABL gene positive CML iii.)
Planned for imatinib mesylate therapy for chronic
phase CML. Exclusion criteria:- (Patients with i.)
Serum   bilirubin, ASG or ALT, creatinine level of
more than twice of upper limit of normal range. ii).
Eastern Cooperative Oncology Group performance
status score of e 3.iii) Grade III/IV cardiac problem
as defined by the New York Heart Association
criteria iv) on any other anticancer therapy except
hydroxyurea (if needed) or the drugs which interact
with imatinib (CYP3A4 inhibitors or inducers).
Institutional ethics committee approval was taken
and written informed consent was taken from all the
patients after explaining the risks and benefits of the
study in the languages they understood.
Study design: After taking informed consent and
baseline evaluation of each included patient, imatinib
mesylate (Gleevec, Novartis - provided free through
Gleevec International Patients Assistance
Programme or GIPAP, Max Foundation, USA)
therapy was started as the single oral dose of 400
mg or 250 mg/m2 per day in chronic phase. Patients
were followed up for the maximum duration of 12
months. All adverse events during treatment were
recorded in a proforma Toxicities were graded
according to Common Toxicity Criteria of National
Cancer Institute.12 Dose adjustment were done
during toxicities according to standard guideline.13
Causality assessment of reported adverse events
was done using WHO-UMC system.14
Result
Adverse events were reported in 36 chronic phase
CML patients on imatinib therapy. A total of 222
adverse events were reported during 12 months of
therapy, which were evaluated for time of onset,
period of persistence, treatment needed and alteration
of therapy are shown in fig 1.and table 2, 3  & 4
respectively.
No treatment of adverse events was needed in 68%
of cases. Only symptomatic treatment was needed
in about 28% of cases while about 5% required
specific therapy .Therapy was not altered for about
88% of adverse events. Drug was withheld only in
hematological toxicities, mainly grade II/III
thrombocytopenia and grade III neutropenia. Drug
withhold followed by permanent dose decrement was
needed in case of prolonged thrombocytopenia in
about 5 cases.
Commonly Reported Adverse Events (Table 1)
Table 1. Adverse events of imatinib in Indian CML-CP patients (n=36);
Total No. of adverse events (AEs) = 222
A. Hematological adverse events
Adverse Events Grade I/II Grade III/V In total no. of Total
(In patients) (In patients) patients(%) (% of total
No. % No. % adverse events)
Thrombocytopenia 15 41.7 7 19.4 22 (61) 54 (24.3)
Leucopenia 9 25.0 3 8.3 12 (33.3)
Neutropenia 10 27.8 3 5.6 12 (33.3)
Anemia 7 19.4 1 2.8 8 (22.2)
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B. Non-hematological adverse events
Adverse Events Grade I/II Grade III/V Total No. Total (% of
No. % No. % (%) total AEs)
Musculoskeletal 38 (17.1)
Muscle Pain 10 27.8 1 2.8 11 (30.6)
Muscle cramp 12 33.3 1 2.8 13 (36.1)
Arthralgia 8 22.2 8 (22.2)
Fatigue 6 16.7 6 (16.7)
Dermatological 35 (15.8)
Skin rash 10 27.8 1 2.8 11 (30.6)
Pruritus/itching 4 11.1 4 (11.1)
hypo pigmentation 10 27.8 10 (27.8)
Hyper Pigmentation 4 11.1 4 (11.1)
Nail bed Pigmentation 3 8.3 3 (8.3)
Alopecia/Hair fall 3 8.3 3 (8.3)
GI disturbances 28 (12.6)
Nausea 8 22.2 8 (22.2)
Vomiting 3 8.3 3 (8.3)
Dyspepsia 9 25.0 9 (25)
Diarrhea 2 5.6 2 (5.6)
Constipation 4 11.1 4 (11.1)
Abdominal pain 2 5.6 2 (5.6)
Body weight changes
Weight gain 18 50.0 4 1.8 22 (61.1)
Weight loss 2 5.6 2 (5.6)
Superficial edema 17 (7.7)
Facial puffiness 14 38.9
Pedal/Ankle 2 5.6 1 2.8 3 (8.3)
Liver toxicity 9 (4.1)
OT/PTá 1 2.8 1 (2.8)
ALPá 6 16.7 6 (16.7)
Bilirubiná 1 2.8 1 (2.8)
Total Proteinâ 1 2.8 1 (2.78)
Others 17 (7.7)
Headache 5 13.9 5 (13.9)
Dizziness 1 2.8 1 (2.8)
Loss of appetite 2 2.8 1 (2.8)
Blurring of vision 1 2.8 1 (2.8)
Decreased vision 1 2.8 1 (2.8)
Pleural effusion 1 2.8 1 (2.8)
Epistaxis 1 2.8 1 (2.8)
Gum bleed 1 2.8 1 (2.8)
Livedo reticularis (legs) 1 2.8 1 (2.8)
Subcojunctival hemorrhage 1 2.8 1 (2.8)
Restlessness 1 2.8 1 (2.8)
Generalized skin edema 1 2.8 1 (2.8)
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Table 2: Onset of adverse events in Indian CML-CP patients (n=36)
Onset of Adverse < 4 wks 5wk - 3m Total < 3m 4m  -  6m 7m  -  12m
events No. % No. % No. % No. % No. %
Total (222) 99 44.6 80 36.0 179 80.6 32 14.4 11 5.0
Musculoskeletal 24 10.8 6 2.7 30 13.5 8 3.6 1 0.5
GI disturbances 21 9.5 5 2.3 26 11.7 1 0.5 1 0.5
Hematological 16 7.2 26 11.7 42 18.9 8 3.6 4 1.8
Dermatological 12 5.4 18 8.1 30 13.5 3 1.4 2 0.9
Superficial edema 8 3.6 4 1.8 12 5.4 5 2.3 0 0.0
Liver toxicity 3 1.4 4 1.8 7 3.2 1 0.5 1 0.5
Body weight changes 3 1.4 14 6.3 17 7.7 6 2.7 1 0.5
Others 12 5.4 3 1.4 15 6.8 0 0.0 1 0.5
Table 3: Period of persistence of adverse events of imatinib in Indian CML-CP patients (n=36)
Adverse events < 4 wks 5wk - 3m Total < 3m 4m  -  f/u
No. % No. % No. % No. %
Total (222) 85 38.8 58 26.1 143 64.4 79 35.6
Hematological 34 15.3 15 6.8 49 22.1 5 2.3
GI disturbances 17 7.7 4 1.8 21 9.5 7 3.2
Musculoskeletal 14 6.3 20 9.0 34 15.3 4 1.8
Dermatologic 12 5.4 8 3.6 20 9.0 15 6.8
Superficial edema 1 0.5 7 3.2 8 3.6 9 4.1
Body weight changes 0 0.0 2 0.9 2 0.9 22 9.9
Liver toxicity 0 0.0 0 0.0 0 0.0 9 4.1
Others 7 3.2 2 0.9 9 4.1 8 3.6
Table 4: Treatment of adverse events of imatinib in Indian CML-CP patients (n=36)
Adverse events Symptomatic treatment Specific Treatment Total
No. % No. % No. %
61 27.5 10 4.5 71 32.0
Musculoskeletal 28 12.6 - 0.0 28 12.6
GI disturbances 19 8.6 - 0.0 19 8.6
Dermatological 13 5.9 1 0.5 14 6.3
Headeche 1 0.5 - 0.0 1 0.5
Pleural effusion - - 1 0.5 1 0.5
Superficial edema - - 4 1.8 4 1.8
Anaemia - - 4 1.8 4 1.8
Table 5: Causality assessment of AEs reported during imatinib therapy in CML-CP patients
(n=36) using WHO-UMC system;
Total AEs=222, Total types of AEs = 40
Causality terms Certain Probable/likely Possible Unlikely Inaccessible/Unclassifiable
AEs(Total = 222) 46 124 47 2 3
        % 20.7 55.9 21.2 0.9 14
None of the AEs was in Conditional/unclassified category
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Table 6: Comparison of adverse events of imatinib reported in our study with Western studies 6,7
and  Indian studies 10.11
Common Adverse Our study Kantarjian6 IRIS7 Arora10 Deshmukh11
events (All grades) N = 36 N = 532 N=51 N =73 N =97
(% patients) % % % % %
Weight gain 61.1 30.3 14.3 61.6 38
Edema 47.2 61.1 56.4 49.3 63.9
Muscle cramp 36.1 49.9 39.6 16.7
Myalgia 30.6 20.2 22.9 27.8
Skin rash 30.6 35 35.9 14.1 21.6
Hypo pigmentation 27.8 - - 41.2 73
Dyspepsia 25 17 16.2 16.7
Nausea 22 56.5 44.4 68
Arthralgia 22.2 19.8 30.7 20.3
Fatigue 16.7 18.4 35.6 11.3
Headache 13.9 13 31.4 19.2
Pruritus 11.1 9 7.5 5.6
Vomiting 8.3 23 18.4 -
Diarrhea 5.6 29 34.6 4.2
Abdominal Pain 5.6 19 29.4 -
Hematological
Thrombocytopenia 61 19.9 64.4 98 17.5
Leucopenia 33.3 23.7 - 63.7
Neutropenia 33.3 35.1 75.1 20.6
Anemia 22.2 7.1 47.7 37.6
Elevated liver Enzymes 16.7 43.2 23.6
Weight gain was the most common non-
hematological event reported in more than 60% of
patients. Average weight gain was 6.4. kg (median
5.5kg) which ranged from 2 to 14 kg. The common
onset of weight gain was between one and 3 months
of therapy which continued till the last follow up of
the patient. It was of grade I/II mainly, where no
treatment and alteration in the therapy were required.
Superficial edema, presented as facial puffiness or per
orbital edema and pedal edema, was the 2nd most
common non-hematological effect seen in about 50% of
patients. It started commonly within 3 months of therapy
and continued till the last follow up. Only few patients
needed low dose furosemide for unresolved edema and
none of them needed drug withhold or dose decrement.
Muscle cramp and myalgia were reported in about
one third of patients. Mostly started within the first
month of the therapy and persisted for less than 3
months. Almost all of the patients required analgesics
for pain relief and none of them needed drug withhold.
Skin rashes were reported in about 30% of patients
as papular lesions at upper limbs or back within 3
months of therapy and resolved within one month
with symptomatic treatment only, for associated
itching.
Hypo pigmentation   reported as fair exposed body
parts in abut 28% of patients within 3 months of
therapy and continued till last follow up. None of
them required any treatment or alteration in the
therapy.
Nausea and Dyspepsia were reported about 25%
of patients within month of therapy and resolved
within one month with antacids only.
Arthralgia and general body fatigue were other
common non-hematological effects, reported within
3 months of therapy and continued for less than 3
months. Arthralgia required pain killers only while
no treatment was needed for fatigue.
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Hematological toxicity; Thrombocytopenia was the
most common toxicity reported in about 60% of
patients. Common onset was within 3 months of
therapy which resolved with drug   withhold for about
2 weeks but permanent dose decrement was needed
in some cases due to recurrence of grade III toxicity.
Total leukocyte count with neutropenia  an anemia
were reported as part of general myelosuppression.
Drug was withheld in high grades of neutropenia
Iron and folic acid supplementation were given for
anemia.
Causality Assessment
Causality assessment of adverse events, reported
during the imatinib therapy was done using WHO-
UMC System14 and shown in table 5 .
Discussion
This was a prospective, open-label, non-comparative,
and hospital based study in which 36 chronic myeloid
leukemia patients in the chronic phase of the disease
were started on imatinib mesylate therapy and a total
of 222 adverse events were recorded for over 12
months of therapy.
Adverse events in our study (Table 1) can be
compared with adverse events reported in Kantarjian
study6, IRIS study7, Indian studies10, 11 (table 6) and
show differences in frequencies which may be due
to different genetic make up of Western and Indian
population which respond differently to the drug.
Other reasons may be different duration of follow
up and sample size of the studies which were lesser
in our study as compare to Western studies. Even
after so many differences in studies the general trend
of the common adverse events   reported in our study
i.e. weight gain, edema, myalgia, arthralgia,
thrombocytopenia is similar to Indian studies. 10,11
Hypo pigmentation (fair body color) reported in our
study is consistent with previous Indian studies which
was not reported in landmark Western studies 6,7
may be due to easy appreciation of color change in
dark brown color of Indian patients. The hypothesis
of pigmentary changes is inhibition of c-Kit imatinib
which has a crucial role in melanogenesis, the center
of melanocyte homeostasis and of   ultraviolet  B-
induced pigmentation.
Less common adverse events i.e. alopecia, dizziness,
weight loss, constipation and anorexia reported in
our study were also reported in IRIS study.7 Hyper
pigmentation of body reported in four patients were
also reported in four patients was consistent with
Arora et al study but not reported in Western studies.
Some uncommon adverse events were also reported
in the study i.e. nail bed pigmentation in 3 patients
which was not reported in IRIS7 and study by Arora
et al10, pleural effusion in one patient which has been
reported in a case report by Breccia et al.15
Most of the adverse events (80%) occurred within
3 months of the therapy, were musculoskeletal,
gastrointestinal and hematological disturbances
mainly and persisted for about one to three months.
The early occurrence of these reactions may be
attributed to the myelosuppression and some unknown
mechanisms for which body develops tolerance
within few months. Some early reactions like GI
disturbances may be attributed to local irritation of
gastric mucosa and stimulation of CTZ in brain.
Adverse events, reported after 3 months of therapy
and continued till last follow up were weight gain,
superficial edema and hypo pigmentation. Fluid
retention, the cause of weight gain and edema might
be starting early but appreciated at around three
months. Tolerance might be developing to these
effects also, so initial rise in weight becomes slow in
the later stage of the therapy. Hypo pigmentation
which has been hypothesized due to inhibition of c-
kit gene, which has role in melanogenesis, presents
as delayed effect as transcription inhibitors, as
evidenced by other molecules, takes weeks to show
their effect and appreciable change in body color
takes time.
Most of the events were mild to moderate requiring
only symptomatic treatment with analgesics for
myalgia, arthralgia and cramps in initial days but
tolerated well later. Specific therapy was low dose
jurosemide for unresolved edema and iron for
anemia. These findings are also consistent with
previous studies. 6,7,10.11
Drug was well tolerated and withhold was not needed
in 88% of adverse events except in grade II/III
thrombocytopenia and grade III neutropenias where
it was done for about one to two weeks within initial
3 months of therapy. But in some cases more than
two weeks of drug withhold was required and
permanent dose decrement was done if toxicity was
recurring  or not resolving. In Knatarjian et at study6
, drug was interrupted for 2 weeks and dose was
decreased to 300 mg if toxicity was unresolved to
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lower grade. Arora et al10 needed dose interruptions
at median duration of 8 weeks and stopped for a
median duration of 3 weeks.
Casual relationship of the imatinib mesylate therapy
with reported adverse events was established using
WHO-UMC criteria. Most of the events (56%) i.e.
edema, muscle pain, skin rashes, weight gain,
pigmentary changes, were having probable
relationship with the imatinib therapy as these could
not be explained with the disease, or other concurrent
or past drug therapy. Only hematological reactions
(21%) were having certain relationship with the
therapy because counts recover after drug withhold
and fall again on restarting the drug. Rest of the
reactions i.e. fatigue, weight loss  , anemia, dyspepsia
were having possible relationship with the therapy
(21%) as these can be explained with both drug
therapy as well as disease or concurrent folic acid
and iron supplementation.
Conclusion
Imatinib was well tolerated therapy, having only mild
to moderate grade of toxicities, mostly within 3
months of therapy and most of them persisted for
less than 3 months of duration, requiring only
symptomatic treatment and drug withhold or dose
decrement in only few cases. Frequency of adverse
events was found to be different  in Western studies
but further studies need to be done for conclusion.
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